The invention provides novel pyrophosphate synthase inhibitors of formula I and formula II as well salts thereof; the invention also provides compositions comprising such inhibitors and methods for their use. ##STR00001##

It is intended to provide a novel bisphosphonic acid compound or a salt thereof which shows a remarkable inhibitory effect on ectopic calcification, and a pharmaceutical composition comprising the same. The present invention provides a bisphosphonic acid compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof: ##STR00001##
wherein represents a single bond or a double bond; A represents a saturated cyclic hydrocarbon or a saturated heterocyclic ring comprising a sulfur atom or an oxygen atom; and R.sup.1 and R.sup.2 each independently represent an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aryloxy group, a haloalkoxy group, a haloalkyl group, a halogen atom or a hydrogen atom.

The invention provides a radically polymerizable compound wherein an acid group is joined via a spacer group to a polyethyleneimine group. The polyethyleneimine group has at least one radically polymerizable group in the side chain and/or terminally. The invention relates further to a process for preparing such compounds by cationic polymerization of oxazolines, to the use of such compounds as constituents of a dental material, and to a dental material comprising the compounds of the invention.

A novel metal organic framework, EMM-39, is described having the structure of UiO-66 and comprising bisphosphonate linking ligands. EMM-39 has acid activity and is useful as a catalyst in olefin isomerization. Also disclosed is a process of making metal organic frameworks, such as EMM-39, by heterogeneous ligand exchange, in which linking ligands having a first bonding functionality in a host metal organic framework are exchanged with linking ligands having a second different bonding functionality in the framework.

A novel metal organic framework, EMM-42, is described having the structure of UiO-66 and comprising bisphosphonate linking ligands. EMM-42 has acid activity and is useful as a catalyst in olefin isomerization. Also disclosed is a process of making metal organic frameworks, such as EMM-42, by heterogeneous ligand exchange, in which linking ligands having a first bonding functionality in a host metal organic framework are exchanged with linking ligands having a second different bonding functionality in the framework.

It is intended to provide a novel bisphosphonic acid compound or a salt thereof which shows a remarkable inhibitory effect on ectopic calcification, and a pharmaceutical composition comprising the same. The present invention provides a bisphosphonic acid compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof:

##STR00001##

wherein represents a single bond or a double bond; A represents a saturated cyclic hydrocarbon or a saturated heterocyclic ring comprising a sulfur atom or an oxygen atom; and R.sup.1 and R.sup.2 each independently represent an alkyl group, an alkenyl group, an alkynyl group, an alkoxy group, an aryloxy group, a haloalkoxy group, a haloalkyl group, a halogen atom or a hydrogen atom.

A novel metal organic framework, EMM-39, is described having the structure of UiO-66 and comprising bisphosphonate linking ligands. EMM-39 has acid activity and is useful as a catalyst in olefin isomerization. Also disclosed is a process of making metal organic frameworks, such as EMM-39, by heterogeneous ligand exchange, in which linking ligands having a first bonding functionality in a host metal organic framework are exchanged with linking ligands having a second different bonding functionality in the framework.

A novel metal organic framework, EMM-42, is described having the structure of UiO-66 and comprising bisphosphonate linking ligands. EMM-42 has acid activity and is useful as a catalyst in olefin isomerization. Also disclosed is a process of making metal organic frameworks, such as EMM-42, by heterogeneous ligand exchange, in which linking ligands having a first bonding functionality in a host metal organic framework are exchanged with linking ligands having a second different bonding functionality in the framework.

The present invention relates to a new class of polyaminomethylene phosphonate derivatives with low phosphorous content and to processes for the preparation thereof. The compounds of the invention are useful for the preparation of additives that prevent the segregation of solids from water and aqueous solutions or dispersions acting as sequestering agents, precipitations inhibitors, dispersants and anti-scale agents in different industrial fields.

The compounds object of this invention are prepared by reacting diethylenetriamine with an epoxide, preferably ethylene oxide, followed by phosphonomethylation of the functionalized polyamines obtained in the previous step by reaction with an aqueous solution of phosphorous acid and formaldehyde in the presence of an acid. The reaction products are usually obtained as a mixture having different substitution degree and patterns.

The mixture can be used as chelating and sequestering agents, precipitations inhibitors, dispersants, boosters in laundry detergents and anti-scale agents; in admixture with other functional agents, carriers, vehicles, excipients suitable for the considered use and field of application.

Disclosed are methods and compositions which may be utilized to inhibit and/or deplete non-classical monocytes during a transplantation procedure. The disclosed methods and compositions may be utilized in order to reduce damage to organs and tissues during a transplantation procedure and/or to improve the success rate of the transplantation procedure.